<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> is a disorder characterized by <z:hpo ids='HP_0004419'>recurrent thrombosis</z:hpo> and the presence of antibodies specific to <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the diagnosis of this syndrome is hampered by the lack of a specific laboratory test </plain></SENT>
<SENT sid="2" pm="."><plain>In this study an ELISA for the measurement of antibodies to solid-phase beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta2-GPI) was established and compared with anticardiolipin antibodies for diagnosis of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Significantly elevated levels of antibodies to beta2-GPI were found in <z:hpo ids='HP_0000001'>all</z:hpo> patients with definite <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (median = 91 AU) </plain></SENT>
<SENT sid="4" pm="."><plain>Marginally elevated levels of antibodies to beta2-GPI were observed in 5% of patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE; median = 4 AU), 1% with <z:hpo ids='HP_0001297'>stroke</z:hpo> (median = 3 AU), 13% with <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e> (median = 3 AU), 10% with <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> (median = 3 AU) and 8% with VDRL false-positive serology for <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> (median = 4 AU), but not in patients with rheumatoid factor, <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> or carotid <z:mp ids='MP_0006135'>artery stenosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, significantly raised levels of anticardiolipin antibodies were observed in 100% of patients with definite <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, 30% with SLE, 88% with <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e>, 94% with <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e>, 62% with <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e>, 9% with <z:hpo ids='HP_0002923'>rheumatoid factor-positive</z:hpo> sera, 74% VDRL false-positive serology for <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e>, 47% with <z:hpo ids='HP_0001297'>stroke</z:hpo> and 0% with carotid <z:mp ids='MP_0006135'>artery stenosis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>This solid-phase assay for antibodies to beta2-GPI is highly specific for the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and represents an advance in the laboratory diagnosis of this disorder </plain></SENT>
</text></document>